Actively Recruiting
Evaluating Safety, Pharmacodynamics, and Efficacy of SKY-0515 for Huntingtons Disease in Adults 25 in a Randomized Placebo-Controlled Trial
Led by Skyhawk Therapeutics, Inc. · Updated on 2026-10-29
400
Participants Needed
31
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SKY-0515, an oral drug, in adults aged 25 and older with genetically confirmed Huntingtons Disease HD. This randomized, double-blind, placebo-controlled trial aims to study the drugs safety, how it affects the body, and its ability to reduce harmful proteins linked to HD. HD is a rare inherited condition caused by a mutation in the HTT gene, leading to nerve cell damage and worsening motor, cognitive, and psychiatric symptoms. SKY-0515 targets reducing mutant huntingtin protein and PMS1 protein, which contribute to disease progression. Participants will be randomly assigned to receive one of three doses of SKY-0515 or a matching placebo once daily by mouth. The treatment period lasts 18 months. The study evaluates multiple doses to find the optimal level for reducing harmful proteins and improving symptoms. The trial is conducted across multiple sites and includes thorough monitoring and testing. During the study, participants will undergo blood tests, MRI scans, and clinical assessments, including the Unified Huntingtons Disease Rating Scale UHDRS. Researchers will measure changes in motor function, total functional capacity, independence, and cognitive tests over 72 weeks. Safety monitoring and efficacy evaluations will continue throughout the treatment, with the main outcome being the change in a composite score of HD symptoms. The trial is expected to be completed by August 2029.
CONDITIONS
Brief Title
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Research Team
S
Study Director, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here